HighTower Advisors LLC Has $1.02 Million Stock Holdings in ARK Genomic Revolution ETF (BATS:ARKG)

HighTower Advisors LLC reduced its holdings in ARK Genomic Revolution ETF (BATS:ARKG) by 16.4% in the 4th quarter, HoldingsChannel reports. The fund owned 43,237 shares of the company’s stock after selling 8,472 shares during the period. HighTower Advisors LLC’s holdings in ARK Genomic Revolution ETF were worth $1,018,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Hemington Wealth Management grew its stake in shares of ARK Genomic Revolution ETF by 44.6% in the fourth quarter. Hemington Wealth Management now owns 1,310 shares of the company’s stock worth $30,000 after purchasing an additional 404 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new position in shares of ARK Genomic Revolution ETF in the fourth quarter worth approximately $45,000. National Bank of Canada FI boosted its holdings in ARK Genomic Revolution ETF by 28.4% in the third quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock valued at $106,000 after acquiring an additional 920 shares during the last quarter. ARK Investment Management LLC increased its position in ARK Genomic Revolution ETF by 72.7% during the 4th quarter. ARK Investment Management LLC now owns 5,989 shares of the company’s stock valued at $141,000 after purchasing an additional 2,521 shares during the period. Finally, IHT Wealth Management LLC bought a new position in ARK Genomic Revolution ETF during the 3rd quarter worth approximately $203,000.

ARK Genomic Revolution ETF Stock Performance

Shares of BATS ARKG opened at $22.50 on Thursday. ARK Genomic Revolution ETF has a 52-week low of $21.56 and a 52-week high of $31.16. The company’s 50 day moving average price is $25.43 and its 200-day moving average price is $25.04.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.